Physician profile
Mark A Mcconn
NPI 1952361354
$3,296.32
in general payments reported to CMS, 2019-2025
34 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $928 · 2021: $1,132 · 2022: $177 · 2023: $34.24 · 2024: $14.66 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $767.87 | 2019-2021 | |
| Abbvie INC. | $257.26 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $234.24 | 2019-2021 | |
| Allergan, INC. | $227.87 | 2019-2022 | |
| Pfizer INC. | $220.41 | 2019-2022 | |
| Amarin Pharma, INC. | $210.46 | 2019-2021 | |
| Lilly USA, LLC | $165.64 | 2019-2024 | Mounjaro |
| Galderma Laboratories, L.P. | $124.96 | 2020 | |
| Leo Pharma INC. | $108.20 | 2025 | Anzupgo |
| Triad Life Sciences INC. | $101.25 | 2022 | |
| Genentech USA, INC. | $87.22 | 2020-2021 | |
| Ibsa Pharma INC. | $73.62 | 2021 | |
| Janssen Pharmaceuticals, INC | $71.98 | 2019 | |
| Mallinckrodt Hospital Products INC. | $62.64 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $57.89 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $47.95 | 2020-2021 | |
| Merz North America, INC. | $47.25 | 2019 | |
| Antares Pharma, INC. | $46.13 | 2019 | |
| Amgen INC. | $45.15 | 2019 | |
| Glaxosmithkline, LLC. | $34.24 | 2023 | Arexvy, Shingrix |
| Philips North America LLC | $33.08 | 2021 | |
| Sunovion Pharmaceuticals INC. | $28.35 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $27.04 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $23.84 | 2021 | |
| Vifor Pharma, INC. | $23.18 | 2019 | |
| Eisai INC. | $21.39 | 2021 | |
| Currax Pharmaceuticals LLC | $17.13 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.00 | 2019 | |
| Merck Sharp & Dohme LLC | $13.48 | 2019 | |
| Fidia Pharma USA INC. | $11.88 | 2019 | |
| Biofrontera INC. | $5.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mcconn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.